Trial Profile
Prevention of Nausea and Vomitting Associated With Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used With Highly Emetogenic Preparative Regimens
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 09 Mar 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 05 Dec 2009 Primary endpoint 'Complete control of nausea and vomiting' has been met.
- 05 Dec 2009 Results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.